Form 4: OrbiMed Entities Boost Stake in ImageneBio with Significant Share Acquisition

OrbiMed Advisors and its affiliates have reported an acquisition of common and non-voting common stock in ImageneBio, Inc., increasing their beneficial ownership.

Summary

• OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Genesis GP LLC, all identified as Directors and 10% Owners of ImageneBio, Inc. (IKNA), jointly filed a Form 4.
• On July 25, 2025, OrbiMed acquired 83,611 shares of Common Stock at a price of $2.49 per share.
• Following this transaction, OrbiMed's indirect beneficial ownership includes 287,885 shares of Common Stock held by OrbiMed Private Investments VI, LP (OPI VI) and 7,584 shares of Common Stock held by OrbiMed Genesis Master Fund, L.P. (Genesis Master Fund).
• Additionally, OrbiMed's indirect beneficial ownership includes 465,178 shares of Non-Voting Common Stock held by OPI VI and 13,107 shares of Non-Voting Common Stock held by Genesis Master Fund.
• Each share of Non-Voting Common Stock is convertible into one share of the Issuer's common stock at the holder's option, subject to a 19.99% beneficial ownership limitation that can be adjusted with 61 days' notice.
• OrbiMed Advisors exercises voting and investment power over these securities through a management committee comprising Carl L. Gordon, Sven H. Borho, and W. Carter Neild, all of whom disclaim beneficial ownership of the shares held by OPI VI and Genesis Master Fund.

Sentiment

Score: 8

Explanation: The acquisition of additional shares by a significant institutional investor and 10% owner, OrbiMed, signals strong confidence in ImageneBio's future prospects, which is generally a positive indicator for the company.

Positives

• A significant institutional investor and 10% owner, OrbiMed, increased its stake in ImageneBio, signaling confidence in the company's future prospects.
• The acquisition of 83,611 common shares at $2.49 per share represents a direct investment at a specific valuation.

Risks

• The beneficial ownership of Non-Voting Common Stock is subject to a 19.99% limitation upon conversion to Common Stock, which may restrict immediate full conversion by the holder.
• Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, except to the extent of their pecuniary interest therein, if any.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

OrbiMed is a prominent healthcare-focused investment firm, and its continued investment in ImageneBio suggests ongoing interest and potential in the biotechnology or life sciences sector, aligning with broader trends of investment in innovative healthcare companies.

Management Changes

Corporate Governance

Related Party Transactions

• The transaction involves OrbiMed Advisors LLC and its affiliated entities, OrbiMed Capital GP VI LLC and OrbiMed Genesis GP LLC, which are related parties and collectively hold significant ownership and board representation in ImageneBio, Inc.

Stakeholder Impact

• Shareholders may view this increased stake by a major institutional investor as a positive signal of confidence in the company's valuation and future performance.
• The company's management and board may benefit from the continued strategic alignment and support of a significant investor like OrbiMed.

Key Dates

Recommendation

The acquisition of additional shares by a significant institutional investor and 10% owner, OrbiMed, signals strong confidence in ImageneBio's future prospects. This insider buying activity often precedes positive company developments or reflects an undervalued stock, making it an attractive entry point for investors.

Keywords

ImageneBio, IKNA, OrbiMed Advisors, OrbiMed Capital, OrbiMed Genesis, Common Stock, Non-Voting Common Stock, SEC Form 4, Insider Trading, Share Acquisition, Beneficial Ownership, Biotechnology, Investment